Mild or Moderate Covid-19

被引:998
作者
Gandhi, Rajesh T. [1 ,2 ]
Lynch, John B. [3 ]
del Rio, Carlos [4 ,5 ]
机构
[1] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Washington, Sch Med, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA
[4] Emory Univ, Sch Med, Div Infect Dis, Dept Med, Atlanta, GA 30322 USA
[5] Grady Hlth Syst, Atlanta, GA USA
关键词
DISEASE; 2019; COVID-19; CORONAVIRUS; CHLOROQUINE;
D O I
10.1056/NEJMcp2009249
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mild or Moderate Covid-19 Covid-19 has a range of clinical manifestations, including cough, fever, myalgias, gastrointestinal symptoms, and anosmia. Diagnosis of Covid-19 is commonly made through detection of SARS-CoV-2 RNA by PCR testing of a nasopharyngeal swab or other specimens, including saliva. Antigen tests are generally less sensitive than PCR tests but are less expensive and can be used at the point of care with rapid results. Evaluation and management of Covid-19 depend on the severity of the disease. Patients with mild disease usually recover at home, whereas patients with moderate disease should be monitored closely and sometimes hospitalized. Remdesivir and dexamethasone have demonstrated benefits in hospitalized patients with severe Covid-19, but in patients with moderate disease, dexamethasone is not efficacious (and may be harmful) and data are insufficient to recommend for or against routine use of remdesivir. Infection control efforts center on personal protective equipment for health care workers, social distancing, and testing. The diagnosis of Covid-19 is usually based on SARS-CoV-2 PCR testing of a nasopharyngeal swab or other specimen. Remdesivir and dexamethasone have benefits in hospitalized patients with severe Covid-19, but in patients with moderate disease, dexamethasone is not efficacious and data are insufficient to recommend for or against routine use of remdesivir.
引用
收藏
页码:1757 / 1766
页数:10
相关论文
共 67 条
[1]  
American College of Radiology, 2020, ACR REC US CHEST RAD
[2]  
[Anonymous], 2020, N ENGL J MED, V382, pe101
[3]  
[Anonymous], 2020, ZHONGHUA JIE HE HE H, V17, DOI 10.3760/cma.j.issn.1001-0939.2020.0020
[4]  
Beigel JH, 2020, N ENGL J MED, V383, pXXX
[5]   Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020) [J].
Bhimraj, Adarsh ;
Morgan, Rebecca L. ;
Shumaker, Amy Hirsch ;
Lavergne, Valery ;
Baden, Lindsey ;
Cheng, Vincent Chi-Chung ;
Edwards, Kathryn M. ;
Gandhi, Rajesh ;
Muller, William J. ;
O'Horo, John C. ;
Shoham, Shmuel ;
Murad, M. Hassan ;
Mustafa, Reem A. ;
Sultan, Shahnaz ;
Falck-Ytter, Yngve .
CLINICAL INFECTIOUS DISEASES, 2020, 78 (07) :e83-e102
[6]   A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 [J].
Boulware, David R. ;
Pullen, Matthew F. ;
Bangdiwala, Ananta S. ;
Pastick, Katelyn A. ;
Lofgren, Sarah M. ;
Okafor, Elizabeth C. ;
Skipper, Caleb P. ;
Nascene, Alanna A. ;
Nicol, Melanie R. ;
Abassi, Mahsa ;
Engen, Nicole W. ;
Cheng, Matthew P. ;
LaBar, Derek ;
Lother, Sylvain A. ;
MacKenzie, Lauren J. ;
Drobot, Glen ;
Marten, Nicole ;
Zarychanski, Ryan ;
Kelly, Lauren E. ;
Schwartz, Ilan S. ;
McDonald, Emily G. ;
Rajasingham, Radha ;
Lee, Todd C. ;
Hullsiek, Kathy H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (06) :517-525
[7]   Distribution of SARS-CoV-2 PCR Cycle Threshold Values Provide Practical Insight Into Overall and Target-Specific Sensitivity Among Symptomatic Patients [J].
Buchan, Blake W. ;
Hoff, Jessica S. ;
Gmehlin, Cameron G. ;
Perez, Adriana ;
Faron, Matthew L. ;
Munoz-Price, L. Silvia ;
Ledeboer, Nathan A. .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 154 (04) :479-485
[8]   Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China [J].
Cai, Qingxian ;
Chen, Fengjuan ;
Wang, Tao ;
Luo, Fang ;
Liu, Xiaohui ;
Wu, Qikai ;
He, Qing ;
Wang, Zhaoqin ;
Liu, Yingxia ;
Liu, Lei ;
Chen, Jun ;
Xu, Lin .
DIABETES CARE, 2020, 43 (07) :1392-1398
[9]  
Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI [10.1056/NEJMoa2019014, 10.1056/NEJMx200021]
[10]  
CDC, 2020, Interim Guidance for Antigen Testing for SARS-CoV-2: Summary Table 1